Growth Metrics

Summit Therapeutics (SMMT) Depreciation and Depletion (2016 - 2026)

Summit Therapeutics filings provide 13 years of Depreciation and Depletion readings, the most recent being $44000.0 for Q1 2026.

  • Quarterly Depreciation and Depletion rose 76.0% to $44000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $165000.0 through Mar 2026, up 89.66% year-over-year, with the annual reading at $146000.0 for FY2025, 64.04% up from the prior year.
  • Depreciation and Depletion hit $44000.0 in Q1 2026 for Summit Therapeutics, up from $42000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $99000.0 in Q2 2022 and bottomed at $20000.0 in Q2 2024.
  • Average Depreciation and Depletion over 5 years is $48588.2, with a median of $42000.0 recorded in 2025.
  • The largest annual shift saw Depreciation and Depletion plummeted 70.0% in 2024 before it skyrocketed 110.0% in 2025.
  • Summit Therapeutics' Depreciation and Depletion stood at $88000.0 in 2022, then tumbled by 65.91% to $30000.0 in 2023, then dropped by 26.67% to $22000.0 in 2024, then surged by 90.91% to $42000.0 in 2025, then grew by 4.76% to $44000.0 in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Depreciation and Depletion are $44000.0 (Q1 2026), $42000.0 (Q4 2025), and $42000.0 (Q3 2025).